Human Leukocyte Differentiation Antigen workshop Ⅸ / HLDA9

What is the aims and approaches of HLDA9?

The Human Leukocyte Differentiation Antigen workshop Ⅸ(HLDA9), held in Barcelona, Spain, in December 2010, as with previous HLDA Workshops, is to provide an invaluable and ongoing service to the scientific community. Those present at this meeting represent the efforts of more than 200 laboratories worldwide who have jeoined together that characterize more than 269 CD antigens.

HLDA9 will study a panel of monoclonal antibodies against B cell-associated molecules. Only monoclonal antibodies against known cloned molecules will be included in the panel. Thus, no unknown antibody blind panels will be carried out. Some antibodies against known CD molecules expressed on B cells will also be included in this panel. MAbs will be provided by both researches and companies. HLDA9 focused mainly on studying and validating mAbs against human cell-surface molecules expressed on B cells.

Which is the yield of new CD antigens in HLDA9?

HLDA9 summarizes information about newly designated CD molecules expressed on B cells. The results of their expression analysis of a large panel of mAbs against B-cell-associated molecules on B-cell subsets and plasma cells and leukemias using flow cytometry is presented. An HLDA9 panel of mAbs was also tested against different subsets of dendritic cells and plasmaocytoid dendritic cells. A study characterizing the new molecule FcHL6 is also described herein.

New CD antigens list of HLDA9

Name Alias Function
CD210 IL10R, CDW210A, HIL-10R, IL-10R1, IL10RA Receptor for IL10
CD215 IL15RA Receptor for IL15.
CD270 HveA, TR2, TNFRSF14 Receptor for CD258 and CD272.
CD307a FCRL1 May function in B-cells activation and differentiation.
CD307b FCRL2 May function in B-cells activation and differentiation.
CD307c FCRH3, IFGP3, IRTA3, SPAP2, FCRL3 May function in B-cells activation and differentiation
CD307d FCRH4, IGFP2, IRTA1, FCRL4 May function in B-cells activation and differentiation
CD307e CD307, FCRH5, IRTA2, BXMAS1, PRO820, FCRL5 May function in B-cells activation and differentiation
CD351 FCA/MR, FKSG87, FCAMR Fc receptor that binds IgM with high affinity and IgA with a 10-fold lower affinity
CD352 NTB-A, SLAMF6, LY108 Triggers cytolytic activity only in NK cells expressing high surface densities of natural cytotoxicity receptors
CD353 SLAMF8 Regulates macrophage function; may play a role in B cell lineage commitment
CD354 TREM-1 Stimulates neutrophil and monocyte-mediated inflammatory responses.Triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers
CD355 CRTAM Interaction with CADM1 promotes NK cell cytotoxicity and IFN-gamma secretion by CD8+ cells in vitro as well as NK cell-mediated rejection of tumors expressing CADM3 in vivo
CD357 TNFRSF18, GITR Receptor for TNFSF18
CD358 TNFRSF21 May activate NFkB and promote apoptosis. May activate JNK and be lymphocytes. involved in T-cell differentiation. Required for both normal cell body death and axonal pruning
CD360 IL-21R Receptor for interleukin-21.
CD361 EVDB, D17S376, EVI2B
CD362 Syndecan-2, HSPG, SDC2 Cell surface proteoglycan that bears heparan sulfate
CD363 EDG1, S1P1, ECGF1, EDG-1, CHEDG1, S1PR1 adhesion, endothelial differentiation
CD364 dJ90K10.5, MGC45378, MSMBBP, PI16 Peptidase inhibitor 16